Sarepta therapeutics announces first quarter 2023 financial results and recent corporate developments

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2023. “we are pleased to report another strong quarter of performance serving the duchenne community. with exondys 51, vyondys 53, and amondys 45, we once again exceeded analyst estimates, with total revenue for the quarter reaching $253.5 million and net product revenue standing at $231.5 million and grow.
SRPT Ratings Summary
SRPT Quant Ranking